The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial)
Background: Fluvoxamine (FVX) has been proposed as a potential treatment for severe COVID-19 by the σ-1 receptor agonist, which can reduce cytokine production. However, the efficacy of FVX remains controversial. Methods: A historical retrospective cohort study was conducted in mild to moderate COVID...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Journal of Infection and Public Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034123003374 |
| _version_ | 1797615949786906624 |
|---|---|
| author | Taweegrit Siripongboonsitti Kriangkrai Tawinprai Paruspak Payoong Nithi Mahanonda |
| author_facet | Taweegrit Siripongboonsitti Kriangkrai Tawinprai Paruspak Payoong Nithi Mahanonda |
| author_sort | Taweegrit Siripongboonsitti |
| collection | DOAJ |
| description | Background: Fluvoxamine (FVX) has been proposed as a potential treatment for severe COVID-19 by the σ-1 receptor agonist, which can reduce cytokine production. However, the efficacy of FVX remains controversial. Methods: A historical retrospective cohort study was conducted in mild to moderate COVID-19 patients, 2:1 ratio of standard of care (SOC) and FVX treatments to assess the effectiveness of FVX in preventing deterioration by the fifth day of treatment. Results: Of 752 eligible patients, 234 received FVX while 518 received SOC, and there was no significant difference in the effectiveness of FVX and SOC in preventing clinical deterioration. On the fifth day after treatment, 86.1 % of patients in the FVX-treated group did not experience clinical deterioration compared to 78.7 % in the SOC group. Notably, the FVX group had higher rates of pneumonia development and hospitalization, requiring more oxygen supplementation while showing less reduction in viral shedding than the SOC group. However, no difference in mechanical ventilation use, ICU admission, and survival was observed. Conclusion: Fluvoxamine treatment is failed to demonstrate effectiveness in preventing deterioration in mild to moderate COVID-19 and may lead to a higher incidence of pneumonia, hospitalization, and oxygen supplementation, necessitating careful consideration before prescribing the drug for COVID-19. |
| first_indexed | 2024-03-11T07:34:14Z |
| format | Article |
| id | doaj.art-c4d20189180446a394ad9b6d69381a21 |
| institution | Directory Open Access Journal |
| issn | 1876-0341 |
| language | English |
| last_indexed | 2024-03-11T07:34:14Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Infection and Public Health |
| spelling | doaj.art-c4d20189180446a394ad9b6d69381a212023-11-17T05:25:46ZengElsevierJournal of Infection and Public Health1876-03412023-12-01161220102016The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial)Taweegrit Siripongboonsitti0Kriangkrai Tawinprai1Paruspak Payoong2Nithi Mahanonda3Division of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand; Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand; Corresponding author at: Division of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.Division of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand; Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, ThailandDivision of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, ThailandChulabhorn Royal Academy, Bangkok, ThailandBackground: Fluvoxamine (FVX) has been proposed as a potential treatment for severe COVID-19 by the σ-1 receptor agonist, which can reduce cytokine production. However, the efficacy of FVX remains controversial. Methods: A historical retrospective cohort study was conducted in mild to moderate COVID-19 patients, 2:1 ratio of standard of care (SOC) and FVX treatments to assess the effectiveness of FVX in preventing deterioration by the fifth day of treatment. Results: Of 752 eligible patients, 234 received FVX while 518 received SOC, and there was no significant difference in the effectiveness of FVX and SOC in preventing clinical deterioration. On the fifth day after treatment, 86.1 % of patients in the FVX-treated group did not experience clinical deterioration compared to 78.7 % in the SOC group. Notably, the FVX group had higher rates of pneumonia development and hospitalization, requiring more oxygen supplementation while showing less reduction in viral shedding than the SOC group. However, no difference in mechanical ventilation use, ICU admission, and survival was observed. Conclusion: Fluvoxamine treatment is failed to demonstrate effectiveness in preventing deterioration in mild to moderate COVID-19 and may lead to a higher incidence of pneumonia, hospitalization, and oxygen supplementation, necessitating careful consideration before prescribing the drug for COVID-19.http://www.sciencedirect.com/science/article/pii/S1876034123003374FluvoxamineFavipiravirCOVID-19SARS-CoV-2SSRI |
| spellingShingle | Taweegrit Siripongboonsitti Kriangkrai Tawinprai Paruspak Payoong Nithi Mahanonda The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) Journal of Infection and Public Health Fluvoxamine Favipiravir COVID-19 SARS-CoV-2 SSRI |
| title | The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) |
| title_full | The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) |
| title_fullStr | The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) |
| title_full_unstemmed | The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) |
| title_short | The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) |
| title_sort | real world effectiveness of fluvoxamine therapy in mild to moderate covid 19 patients a historical cohort study fluvoxa trial |
| topic | Fluvoxamine Favipiravir COVID-19 SARS-CoV-2 SSRI |
| url | http://www.sciencedirect.com/science/article/pii/S1876034123003374 |
| work_keys_str_mv | AT taweegritsiripongboonsitti therealworldeffectivenessoffluvoxaminetherapyinmildtomoderatecovid19patientsahistoricalcohortstudyfluvoxatrial AT kriangkraitawinprai therealworldeffectivenessoffluvoxaminetherapyinmildtomoderatecovid19patientsahistoricalcohortstudyfluvoxatrial AT paruspakpayoong therealworldeffectivenessoffluvoxaminetherapyinmildtomoderatecovid19patientsahistoricalcohortstudyfluvoxatrial AT nithimahanonda therealworldeffectivenessoffluvoxaminetherapyinmildtomoderatecovid19patientsahistoricalcohortstudyfluvoxatrial AT taweegritsiripongboonsitti realworldeffectivenessoffluvoxaminetherapyinmildtomoderatecovid19patientsahistoricalcohortstudyfluvoxatrial AT kriangkraitawinprai realworldeffectivenessoffluvoxaminetherapyinmildtomoderatecovid19patientsahistoricalcohortstudyfluvoxatrial AT paruspakpayoong realworldeffectivenessoffluvoxaminetherapyinmildtomoderatecovid19patientsahistoricalcohortstudyfluvoxatrial AT nithimahanonda realworldeffectivenessoffluvoxaminetherapyinmildtomoderatecovid19patientsahistoricalcohortstudyfluvoxatrial |